A comprehensive view of AbbVie Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AbbVie submits supplemental new drug application to FDA for Atogepant Qulipt, a preventive treatment for chronic migraines in adults; migraines affect 39 million people in US, are highest cause of disability for those under 50 years of age
Published: June 22, 2022 by PR Newswire
FDA approves AbbVie’s Skyrizi injectable to treat moderate to severe active Crohn's disease in adults; drug is first new treatment for moderate to severe active CD in six years
Published: June 20, 2022 by Alliance News
Allergan Aesthetics publishes global trends report on drivers shaping the aesthetics market in the coming five years; report aims to help practitioners, industry players identify key developments, is available on company's website
Published: June 17, 2022 by PR Newswire
AbbVie applies for US, international approval of ABBV-951 foscarbidopa/foslevodopa to treat advanced Parkinson's disease; drug delivered subcutaneously via a pump
Published: May 25, 2022 by SeeNews Pharmaceuticals
AbbVie awarded license option for Cugene’s CUG252 Treg-selective IL-2 mutein injectable to treat autoimmune, inflammatory diseases for US$48.5M; Cugene plans Phase 1b trial in patients with autoimmune, inflammatory diseases during option period
Published: May 17, 2022 by PR Newswire

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count